伊索林德拉克针对TNF-α/STAT3炎症通路来减轻牛皮样皮肤炎的作用
Shuya Sun1, Hao Shen1, Yihe Liu2
1Genetic Skin Disease Center, Jiangsu Provincial Key Laboratory of Dermatology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China.
European journal of pharmacology
|March 8, 2026
概括
一种新型的天然化合物伊索林德拉克通过抑制TNF-α信号传递,有效治疗牛皮. 在小鼠模型中,局部应用减少了炎症,为轻度至中度的牛皮提供了新的治疗方法.
科学领域:
- 皮肤病学和免疫学
- 药理学和药物发现
- 分子生物学分子生物学
背景情况:
- 牛皮涉及一个由瘤缩因子-α (TNF-α) 驱动的促炎级联.
- 现有的TNF-α向生物药物是全身性的,并为轻度至中度的牛皮留下治疗缺口.
- 需要有效的局部治疗来抑制TNF诱导的炎症信号.
研究的目的:
- 确定一种新的,强效的天然小分子药物用于牛皮治疗.
- 阐明确定药物的治疗机制,抑制TNF诱导的炎症信号.
主要方法:
- 高通量选确定了候选小分子.
- 通过局部应用在一种因伊米基莫德 (IMQ) 诱导的牛皮类小鼠模型中评估了伊索林德拉克的疗效.
- RNA测序 (RNA-seq) 分析了TNF-α刺激细胞和小鼠表皮中的转录组变化,以确定机制.
主要成果:
- 伊索林德拉克显示出强大的TNF相关的信号抑制与低细胞毒性.
- 局部用伊索林德拉克显著缓解了IMQ诱导的牛皮样皮肤炎.
- 伊索林德拉克降低了关键炎症因子 (TNF-α,IL-17,S100) 的调节,并抑制了表皮角质细胞中的TNF-α/STAT3通路.
结论:
- 伊索林德拉克通过多种机制表现出显著的抗炎活性.
- 局部用伊索林德拉克显示出作为治疗轻度至中度牛皮的新疗法的潜力.
- 这项研究强调了一种有希望的天然化合物,用于针对性的局部牛皮治疗.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
678
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
678
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
591
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
591
Inflammatory Bowel Disease IV: Pharmacological Management
882
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
882
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
621
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
621
Drugs for Treatment of Ulcerative Colitis in IBD
582
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
582
Antiasthma Drugs: Leukotriene Modifiers
2.1K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.1K

